Literature DB >> 27542972

Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age.

Joann Seo1, Jennifer Ivanovich2, Melody S Goodman2, Barbara B Biesecker3, Kimberly A Kaphingst4,5.   

Abstract

We investigated what information women diagnosed with breast cancer at a young age would want to learn when genome sequencing results are returned. We conducted 60 semi-structured interviews with women diagnosed with breast cancer at age 40 or younger. We examined what specific information participants would want to learn across result types and for each type of result, as well as how much information they would want. Genome sequencing was not offered to participants as part of the study. Two coders independently coded interview transcripts; analysis was conducted using NVivo10. Across result types, participants wanted to learn about health implications, risk and prevalence in quantitative terms, causes of variants, and causes of diseases. Participants wanted to learn actionable information for variants affecting risk of preventable or treatable disease, medication response, and carrier status. The amount of desired information differed for variants affecting risk of unpreventable or untreatable disease, with uncertain significance, and not health-related. Women diagnosed with breast cancer at a young age recognize the value of genome sequencing results in identifying potential causes and effective treatments and expressed interest in using the information to help relatives and to further understand their other health risks. Our findings can inform the development of effective feedback strategies for genome sequencing that meet patients' information needs and preferences.

Entities:  

Keywords:  Breast cancer; Genome sequencing; Information needs; Patient preferences; Return of results

Mesh:

Year:  2016        PMID: 27542972      PMCID: PMC5318287          DOI: 10.1007/s10897-016-0006-2

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  53 in total

Review 1.  Disclosure of individual genetic data to research participants: the debate reconsidered.

Authors:  Annelien L Bredenoord; Hester Y Kroes; Edwin Cuppen; Michael Parker; Johannes J M van Delden
Journal:  Trends Genet       Date:  2010-12-27       Impact factor: 11.639

2.  Introduction: Understanding and influencing multilevel factors across the cancer care continuum.

Authors:  Stephen H Taplin; Rebecca Anhang Price; Heather M Edwards; Mary K Foster; Erica S Breslau; Veronica Chollette; Irene Prabhu Das; Steven B Clauser; Mary L Fennell; Jane Zapka
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

3.  Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing.

Authors:  Joon-Ho Yu; Julia Crouch; Seema M Jamal; Michael J Bamshad; Holly K Tabor
Journal:  Am J Med Genet A       Date:  2014-05-20       Impact factor: 2.802

Review 4.  Diagnostic clinical genome and exome sequencing.

Authors:  Leslie G Biesecker; Robert C Green
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

5.  Personal genome research : what should the participant be told?

Authors:  Amy L McGuire; James R Lupski
Journal:  Trends Genet       Date:  2010-04-08       Impact factor: 11.639

6.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

Authors:  Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2013-04-29       Impact factor: 13.506

Review 7.  Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Authors:  Robert L Yauch; Jeff Settleman
Journal:  Curr Opin Genet Dev       Date:  2012-02-07       Impact factor: 5.578

8.  Practices and policies of clinical exome sequencing providers: analysis and implications.

Authors:  Seema M Jamal; Joon-Ho Yu; Jessica X Chong; Karin M Dent; Jessie H Conta; Holly K Tabor; Michael J Bamshad
Journal:  Am J Med Genet A       Date:  2013-05       Impact factor: 2.802

9.  Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009.

Authors:  Rebecca H Johnson; Franklin L Chien; Archie Bleyer
Journal:  JAMA       Date:  2013-02-27       Impact factor: 56.272

10.  Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Authors:  Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner
Journal:  J Nucl Med       Date:  2014-09-11       Impact factor: 10.057

View more
  1 in total

1.  How do providers discuss the results of pediatric exome sequencing with families?

Authors:  Sarah A Walser; Allison Werner-Lin; Rebecca Mueller; Victoria A Miller; Sawona Biswas; Barbara A Bernhardt
Journal:  Per Med       Date:  2017-09-04       Impact factor: 2.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.